Clinical significance of golgi protein‐73 as a diagnostic marker for Egyptian patients with colorectal cancer: Preliminary study

BACKGROUND: Colorectal cancer is one of the most common cancers and the leading cause of cancer‐related death worldwide. Early diagnostic methods help in therapeutic success and higher survival rate. Golgi protein 73 (gp73) could help in diagnosis of colorectal cancer at an earlier stage. AIM: A case‐control study aimed to assess serum level of golgi protein 73 (gp73) as a liquid biopsy marker in Egyptian colorectal cancer patients. METHODS AND RESULTS: In the current study, ninty (90) patients were included and classified into three groups; thirty (30) patients with Colorectal cancer (CRC) as study group; 30 patients (20 patients with irritable bowel disease and 10 patients with rectal polyps) as pathological control and 30 healthy adult individuals as normal control. The diagnosis was based on the history, clinical, laboratory, endoscopic, and histological data. Golgiprotein 73 (GP73) was measured by ELISA immunoassay Kit. Serum GP73 level was higher in CRC patients than pathological control group and normal control group with high sensitivity and specificity p < .005. CONCLUSION: GP73 alone or combined with Carcinoembryonic antigen (CEA) may be good diagnositic marker in CRC. However large studies are warranted on different stages of the disease to assess its diagnostic and prognositic value.